MK-927: A Topical Carbonic Anhydrase Inhibitor: Dose Response and Duration of Action

Eve J. Higginbotham, Michael A. Kass, Erik A. Lippa, Randal L. Batenhorst, Deborah L. Panebianco, Jacob T. Wilensky

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


The dose response to a single topical administration of the carbonic anhydrase inhibitor MK-927 was investigated in 24 patients with primary open angle glaucoma or ocular hypertension. Three concentrations of MK-927 (2%, 1%, and 0.5%) and placebo were administered in a two-center, double-masked, randomized, placebo-controlled, four-period crossover study. MK-927 at the 0.5% concentration appeared to be minimally effective in reducing intraocular pressure. A single topical dose of 1% MK-927 resulted in a significantly greater percent reduction in intraocular pressure for up to 6 hours when compared with treatment with placebo. Similarly, a single dose of 2% MK-927 significantly lowered intraocular pressure for 8 hours compared with treatment with placebo. The pressure reduction from baseline measured 23.7% and 11.3% at 8 hours after instillation of a single drop of 2% MK-927. The medication was well tolerated and appeared to lower intraocular pressure in a dose-dependent fashion.

Original languageEnglish
Pages (from-to)65-68
Number of pages4
JournalArchives of Ophthalmology
Issue number1
StatePublished - Jan 1990


Dive into the research topics of 'MK-927: A Topical Carbonic Anhydrase Inhibitor: Dose Response and Duration of Action'. Together they form a unique fingerprint.

Cite this